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Signal transductionIn most eukaryotic cells, mitochondria have various essential roles for proper cell function, such as energy pro-
duction, and in mammals mitochondria also act as a platform for antiviral innate immunity. Mitochondrial-
mediated antiviral immunity depends on the activation of the cytoplasmic retinoic acid-inducible gene I
(RIG-I)-like receptors (RLRs) signaling pathway, and on the participation of mitochondrial antiviral signaling
(MAVS), which is localized on the mitochondrial outer membrane. After RNA virus infection, RLRs translocate
to themitochondrial surface to interact withMAVS, and the adaptor protein undergoes a conformational change
that is essential for downstream signaling, although its structural features are poorly understood. Herewe exam-
ined the MAVS-regulatory mechanism on the mitochondrial outer membrane using bioluminescence resonance
energy transfer (BRET) in live cells. Using a combination of BRET and functional analysis, we found that the ac-
tivated MAVS conformation is a highly ordered oligomer, at least more than three molecules per complex unit
on the membrane. Hepatitis C virus NS3/4A protease and mitofusin 2, which are known MAVS inhibitors, inter-
ferewithMAVS homotypic oligomerization in a distinctmanner, each differentially altering the active conforma-
tion of MAVS. Our results reveal structural features underlying the precise regulation of MAVS signaling on the
mitochondrial outer membrane, and may provide insight into other signaling systems involving organelles.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
RNA viruses gain entry into host cells either through endocytosis,
where the plasma membrane engulfs the virion, resulting in the re-
lease of the virion constituents into the cell, or through membrane fu-
sion with the plasma membrane, resulting in the immediate release
of viral replication machinery and incorporation of the corresponding
nucleic acids into the host cytoplasm. To counter the plasma mem-
brane fusion of RNA viruses, vertebrates have evolved the retinoic
acid-inducible gene I (RIG-I)-like receptors (RLRs) pathway, which
detects cytoplasmic viral-derived double-stranded (ds)RNA and in-
duces a signaling cascade to initiate an antiviral innate immune re-
sponse [1,2]. In humans, the RLRs pathway detects several virusesementation; BRET, biolumines-
and recruitment domain; HCV,
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factor 3; MAVS, mitochondrial
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rights reserved.from ﬁve families (Paramyxoviridae, Orthomyxoviridae, Rhabdoviridae,
Flaviviridae, and Reoviridae), which include hepatitis C, Dengue,
Japanese encephalitis, rabies, and inﬂuenza A viruses [3,4].
The initial sensors of intracellular viral RNA are caspase activation and
recruitment domain (CARD)-containing RNA-helicase proteins, RIG-I and
melanoma differentiation-associated gene 5 (MDA5), which differ based
on the size and type of the viral RNA [3–5]. Post-nucleotide recognition
by the RLRs [6,7] leads to translocation of the RNAhelicases to the scaffold
adaptor protein, mitochondrial antiviral signaling (MAVS [8]; also known
as IPS-1 [9], VISA [10], and Cardif [11]), a ubiquitously expressed mito-
chondrial outer membrane protein. Upon the upstream signaling event,
MAVS is proposed to undergo a conformational switch that leads to the
recruitment of various downstream effectors, such as tumor necrosis
factor receptor-associated factor (TRAF) family members and tumor
necrosis factor receptor-associated death domain (TRADD), to form a su-
pramolecular signaling assembly. The mitochondrial hub of the protein
complex, the so-called MAVS signalosome, is essential for upregulation
of the transcriptional factors nuclear factor κB (NF-κB) and interferon
regulatory factor-3 (IRF-3), leading to the rapid production of type I inter-
ferons (IFNs) and proinﬂammatory cytokines [12,13].
Because the prominent function of MAVS signaling is precisely
regulated upon viral infection [13–15], it is crucial to understand
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volved in activating and inactivating MAVS signaling. In fact, these
processes comprise transiently populated states during the signaling
event, making it difﬁcult to directly determine the structure of
MAVS. Further, MAVS signaling occurs on the mitochondrial surface,
so it is somewhat altered when reconstituted under isolated in vitro
conditions. In the present study, we bypassed the practical issues
mentioned above and investigated the MAVS-regulatory mechanism
in live cells using a ﬂuorescence-based assay combinedwith function-
al study. Our results indicated that MAVS undergoes a homotypic in-
teraction, resulting in a highly oligomerized state toward signaling.
The hepatitis C virus (HCV) protease NS3/4A, NOD-like receptor family
member X1 (NLRX1), and mitofusin 2 (Mfn2), all of which are known
MAVS inhibitors [12,13,15], differentially target the MAVS conforma-
tion to inhibit its actions. Based on these ﬁndings, we provide structural
insight into mitochondrial-mediated antiviral signaling.
2. Materials and methods
2.1. Materials and cell cultures
The human embryonic kidney (HEK) 293 cell linewasmaintained in
Dulbecco's modiﬁed Eagle medium (D-MEM; GIBCO BRL, Carlsbad, CA)
supplemented with 1% L-glutamine, 1% penicillin–streptomycin, and
10% bovine calf serum (BCS) at 5% CO2 and 37 °C. The rabbit polyclonal
antibody against humanMAVSwas described previously [16]. Anti-Myc
(9E10) and anti-HA (HA.11) monoclonal antibodies were purchased
from Covance (Princeton, NJ), anti-phospho-IRF-3 (Ser396) rabbit
monoclonal (4D4G), anti-Hsp60, and anti-COX IVpolyclonal (D307) an-
tibodies were obtained from Cell Signaling Technology (Danvers, MA),
and anti-mtHsp70 monoclonal antibody was purchased from Afﬁnity
BioReagents (Golden, CO). Anti-β-actin, anti-Mfn2, and anti-Tom-20
monoclonal antibodies, as well as anti-Mfn1 and anti-cytochrome c
polyclonal antibodies, were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA), anti-GFP antibody was from MBL (Nagoya, Japan),
and anti-OPA-1 monoclonal antibody was from BD Biosciences (San
Jose, CA). Coelenterazine H was purchased from Promega (Madison,
WI). The NLRX1-deﬁcient mouse embryonic ﬁbroblast (MEF) was kind-
ly provided by Jenny Ting (University of North Carolina at Chapel Hill).
All other reagents were of biochemical research grade.
2.2. Plasmid construction and mutagenesis
Polymerase chain reaction (PCR) was performed with PrimeSTAR
DNA polymerase (Takara, Tokyo, Japan). The following oligonucleo-
tide DNA primers were used to generate the complete open reading
frames of the following genes:
humanMAVS: 5′-aaaGCGGCCGCcatgccgtttgctgaagacaagacc (forward),
5′-tttGATATCtcagtgcagacgccgccggtacagcacc (reverse);
hMfn1: 5′-aaaGCTAGCaccATGGGGgcagaacctgtttctccac (forward),
5′-tttGGTACCggattcttcattgcttgaagg (reverse);
hMfn2: 5′-aaaGCTAGCaccATGGGGtccctgctcttctctcgatgc (forward),
5′-tttGGTACCtctgctgggctgcaggtactgg (reverse);
hNLRX1: 5′-aaGCGGCCGCcatgaggtggggccaccatttgcccagggcc (forward),
5′-ttGATATCtcagcttccagagcttcccagctgctccagg (reverse);
rat Tom-22: 5′-aaaGCGGCCGCcatggccgccgccgtcgctgc (forward),
5′-tttGATATCtcagatctttccaggaagtggagg (reverse);
murine Omp-25: 5′-aaGCGGCCGCcatgaacggacgggtgg (forward),
5′-tttGATATCtcaaagctgctttcggtatc (reverse);
Venus: 5′-aaGCTAGCaccatggtgagcaagggcg (forward; 1 A.A.),
5′-ttGCGGCCGCcttgtacagctcgtccatgccg (reverse; 239 A.A.),
5′-ttGCGGCCGCggcggtgatatagacgttg (reverse for Venus(N); 155 A.A.),
5′-aaGCTAGCaccatggacaagcagaagaacggc (forward for Venus(C);
156 A.A.);Renilla luciferase (Rluc): 5′-aaGCTAGCaccatggcttccaaggtgtacgac
cccgagc (forward),
5′-ttGCGGCCGCctgctcgttcttcagcacgcgctcc (reverse).
Fusion-tagged MAVS-expression plasmids were constructed by li-
gating the PCR amplimer into a pcDNA3.1 (−) vector (Invitrogen,
Carlsbad, CA) that encoded either an N-terminal Venus or Rluc tag.
Mutation (C508R) into Venus- or Rluc-MAVS plasmids was intro-
duced by site-directed mutagenesis (Stratagene, La Jolla, CA). The
Myc-tagged versions of MAVS, Mfn1, Mfn2, and their variants were
described previously [16]. The NLRX1 variants were created by ampli-
fying the regions comprising amino acids 1–975 (full length), 40–975
(mature), and 40–560 (NACHT) by using PCR, and ligating the PCR
products into the pcDNA3.1 (−) vector that encoded either an
N-terminal or C-terminal HA-tag. To generate retroviral expression
constructs of NLRX1 variants, each HA-tagged NLRX1 cDNA was
recloned into the retroviral vector pMXs-Puro (Cell Biolabs, San
Diego, CA). The retroviral expression vectors were then transfected
into the platinum packaging cell lines (Cell Biolabs), and the retrovi-
ral supernatant was harvested 48 h post-transfection and used to in-
fect MEF cultures. All constructs used in the present study were
conﬁrmed by DNA sequencing (ABI 3100).
2.3. Dual luciferase reporter assay
Luciferase assays were performed as described previously [17] with a
slight modiﬁcation. In brief, HEK293 cells were plated in 24-well plates
(2×105 cells/well). The following day, the cells were co-transfected
with 50 ng of a luciferase reporter plasmid (p125luc, pELAM, or
pISRE-Luc), 2.5 ng of Renilla luciferase internal control vector phRL-TK
(Promega), and each of the indicated vectors using Lipofectamine 2000
reagent (Invitrogen). An empty vector [pcDNA3.1 (−)] was used to
maintain equivalent amounts of DNA in each well. Cells were harvested
24 h post-transfection and analyzed by a dual-luciferase reporter assay
on the GloMax 20/20n luminometer (Promega).
2.4. BRET saturation assay
All the BRET signals were measured using a Flexstation 3
Microplate Reader (Molecular Devices, Sunnyvale, CA) at 37 °C. For
the assay, HEK293 cells were plated in 12-well plates (2.5×105
cells/well). The following day, the cells were co-transfected with a
constant quantity (5 ng) of Rluc-tagged plasmid and increasing
amounts of Venus-tagged constructs using Lipofectamine 2000.
Empty vector [pcDNA3.1 (−)] was also used to maintain equivalent
amounts of DNA in each well. Twenty hours post-transfection, the
cells were washed once with 1× phosphate-buffered saline (PBS,
pH 7.2), mechanically detached, and collected by centrifugation
(800 g for 5 min). The cell pellets were then resuspended in 80 μL
of Dulbecco's PBS (pH 7.2), and two 40-μL aliquots of cell suspensions
were transferred to each well of white 96-well microplates (duplicate
wells). After adding 10 μL of Rluc substrate (coelenterazine H, 25 μM)
into each sample, followed by 30 s of gentle mixing, luminescence
was measured simultaneously for the donor (λem=475 nm; short
wavelength) and for the acceptor (λem=530 nm; long wavelength).
Saturation data analysis was performed using the following equation,
described previously [18]:
BRET signal ¼ long wavelength½ = short wavelength½ 
− long wavelength½ donor only= short wavelength½ donor only:
2.5. Mitochondrial fractionation and proteolysis
HEK293 cells were washed once with cold 1× PBS (pH 7.2),
scraped off the culture plate, and lysed in 800 μL homogenization
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tol] by 30 strokes in a Dounce homogenizer. The homogenate was
centrifuged at 800 g for 5 min, and the resulting supernatant was fur-
ther centrifuged at 11,000 g for 10 min (4 °C) to precipitate the crude
mitochondrial fraction. After washing the pellet once with the ho-
mogenization buffer, the isolated mitochondrial fraction was
resuspended into homogenization buffer and treated with trypsin
(100 μg/mL) in the absence or presence of 0.05% (w/v) digitonin.
The proteolytic reaction was performed on ice for 15 min, and the re-
actants were subjected to Western blot analysis with the indicated
antibodies.
2.6. Electron microscopy (EM)
For EM, cells were processed as previously described [19]. In brief,
the cells were pre-ﬁxed in 1× PBS containing 2% formaldehyde and
2% glutaraldehyde for 1 h, washed twice with 1× PBS, and
post-ﬁxed with 1% osmium solution at 4 °C. Cells were then washed,
stained with 0.5% aqueous uranyl acetate for 1 h, dehydrated through
a graded series of ethanol, and embedded in Epon. Sections (70 nm)
were cut on an EM UC6 ultramicrotome (Leica, Wetzlar, Germany),
stained with 2% uranyl acetate in 70% ethanol and Reynolds' lead cit-
rate, and analyzed on a JEOL JEM-1010 EM at 80 kV. Images were
recorded with an Olympus Soft Imaging System VELETA CCD camera.
For morphometry, at least 200 mitochondria from individual cells
were scored in total.
2.7. Confocal microscopy
NLRX1−/− MEFs were plated on coverslips in 12-well plates
(4×104 cells/well). The next day, the cells were infected with the ret-
roviral supernatants. Forty-eight hours post-infection, cells were
ﬁxed with 3.7% formaldehyde for 10 min, permeabilized with 0.1%
Triton X-100 in 1× PBS (pH 7.2), and blocked with 5% BCS. The
expressed HA-tagged NLRX1 constructs were detected with antibody
against HA (HA.11) and Alexa Fluor 488-conjugated secondary anti-
body, and mitochondria were visualized by mitochondrial-targeted
red ﬂuorescent protein. Cells were imaged by a Carl Zeiss LSM510
confocal microscope.
3. Results
3.1. Validation of bioluminescence resonance energy transfer (BRET)
constructs
BRET is a powerful tool for evaluating protein–protein interactions
in live cells. Because it does not require an external excitation source,
which often results in photobleaching, BRET provides a comparable
range of biologicalmacromolecular complexes (≤10 nm) [18]. To eluci-
date the structural characteristics of MAVS signaling on the mitochon-
drial outer membrane, we ﬁrst designed two variants of human
MAVS, containing either Venus- or Rluc-fusion tags at their N-termini
(denoted as Venus-MAVS and Rluc-MAVS, respectively). Functionally,
the Venus-MAVS construct was almost identical to the original MAVS
protein we used previously [16], and it potently activated both IFN-β
and NF-κB reporter plasmids in a dose-dependent manner (Fig. 1A).
Consistent with the reporter assay, the overexpression of Venus-
MAVS in HEK293 cells promoted endogenous IRF-3 phosphorylation
(second panel, Fig. 1B), a hallmark of IRF-3 activation. However, co-
expression of NS3/4A (an inhibitor of the RLRs pathway; described in
Section 3.3), a serine protease that cleavesMAVS from themitochondri-
almembrane, impaired the activation of both IRF-3 and NF-κB (far right
lanes, Fig. 1A, B), as previously reported [11,20]. Similarly, the behavior
of the Rluc-MAVS construct was almost identical to that of the Venus-
MAVS (Supplementary Fig. S1). We therefore concluded that theaddition of either fusion tag (approximately 27- or 35-kDa proteins)
to MAVS had no effect on its overall function in signal transduction.
3.2. MAVS homo-oligomerization involved in antiviral signal transduction
We analyzed the structural characteristics of the MAVS-activated
conformation using a BRET-based assay in live cells. The interaction be-
tween Venus-MAVS and Rluc-MAVS was successfully monitored using
a BRET saturation assay (ﬁlled squares, Fig. 1C), which displayed a hy-
perbolic saturation curve characteristic of the speciﬁc interaction [18],
although neither the interaction between Rluc protein and Venus-
MAVS nor that between the fusion proteins (Rluc/Venus) themselves
were observed (Supplementary Fig. S2). To conﬁrm that our observed
MAVS–MAVS interaction was not a result of nonspeciﬁc interactions
and/or aggregation on the mitochondrial membrane, we next tested
the Venus-tagged versions of two mitochondrial outer membrane pro-
teins (Tom-22 andOmp-25) instead of Venus-MAVS, and these proteins
were co-transfected with Rluc-MAVS. Increasing the amounts of either
Venus-Tom-22 or Venus-Omp-25 did not increase the strength of BRET
signals (open triangles or circles, Fig. 1C). Wemapped the region of this
homotypic interaction via the C-terminal region of MAVS (cross sym-
bols, Fig. 1D), which includes the single spanning transmembrane re-
gion (see Supplementary Fig. S3). These results suggest that anchoring
on the mitochondrial outer membrane would be relevant to both
function and protein–protein interaction (Fig. 1D, E, and Supplementary
Fig. S4).
To verify that the observed MAVS–MAVS interaction in live cells
would also form even highly ordered oligomers as previously
reported [21], we sought a complementation assay (bimolecular ﬂuo-
rescence complementation; BiFC) combined with the BRET system
(Supplementary Fig. S5). Neither the N-terminal truncated version of
Venus [Venus(C)] nor its C-terminal truncated [Venus(N)] proteins
fused with MAVS produced a positive ﬂuorescent signal (left images,
Fig. 2A). However, coexpression of both constructs [Venus(N+C)-MAVS]
absolutely complemented the signal in a dose-dependentmanner (green
squares in the right panel, Fig. 2A), indicating that homotypic MAVS in-
teractions, as seen above, caused the functional reconstitution. Most im-
portantly, a positive BiFC BRET saturation curve was observed between
the complemented Venus pair of the proteins and Rluc-MAVS (green
squares, Fig. 2B), demonstrating that the activated MAVS conformation
is a highly ordered oligomer, as we expected of at least more than three
molecules on the outer membrane (Supplementary Fig. S5B). We hy-
pothesized that this conformational change in MAVS molecules might
be due to a drastic membrane dynamics arrangement, because the
ultrastructure of the mitochondrial intermembrane space expanded
(arrowheads in the right panel, Fig. 2C) when the Sendai virus (SeV), a
negative-stranded RNA virus of the Paramyxoviridae family, was infected
into their host cells [the vast majority of mitochondria show an ab-
normal ultrastructure (~89%) when cells are challenged by SeV infection
(Supplementary Fig. S6)].
3.3. NS3/4A abolishes MAVS–MAVS interactions
Studies of the conformational changes in MAVS involved in the sig-
naling allowed us to exploreMAVS in a quiescent state by negative reg-
ulators. We ﬁrst examined the effect of the HCV NS3/4A, which cleaves
MAVS at its cysteine residue at amino acid position 508 [11,20] (left
panel, Fig. 3A). OurMAVS constructswere also inactivated by proteolyt-
ic cleavage, as observed in previous studies (far right lanes, Fig. 1A, B). In
preliminary tests of our BRET assay, we introduced a C508R substitution
into Venus-MAVS and Rluc-MAVS constructs resistant to proteolysis at-
tack by NS3/4A [20] (right panel, Fig. 3A). The C508R variants activated
both IRF-3 and NF-κB in a dose-dependent manner (Fig. 3B, C), indicat-
ing that they were functionally indistinguishable from their wild-type
counterparts, except that they were resistant to NS3/4A attack (far
right lane, Fig. 3C).
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Fig. 1. Structural and functional analyses of MAVS constructs using a BRET assay. (A). HEK293 cells were transfected with empty (mock) or increasing amounts (5, 20, and 50 ng) of
expression vector for Venus-MAVS and with either IFN-β (left) or NF-κB (right) luciferase reporter plasmids. The far right lane (NS3/4A) of both panels indicates that 20 ng of
HA-tagged NS3/4A expression plasmid was co-transfected in the cells (using 50 ng Venus-MAVS). (B). Western blots of post-nuclear lysates from the reporter assay (A) were de-
veloped by immunoblottingwith the indicated antibodies. Anti-β-actinwas used as a loading control of each sample. (C). HEK293 cellswere co-transfectedwith 5 ngRluc-MAVSexpression
plasmid with increasing amounts (0−200 ng) of Venus-tagged MAVS, Tom-22, or Omp-25 plasmids, and analyzed 20 h later using a BRET saturation assay. (D). HEK 293 cells were
co-transfectedwith their pairs of Rluc-MAVS (WT)/Venus-MAVS(WT), Rluc-MAVS (201–540)/Venus-MAVS (201–540), or Rluc-MAVS(1–514)/Venus-MAVS (1–514), and aBRET saturation
assay was performed. The plasmids used in the assay were Rluc vectors (5 ng) and increasing amounts (0−200 ng) of Venus plasmids, respectively. Graphs are plotted as a function of the
ratio of theﬂuorescence of the acceptor (Venus) to the luminescence of the donor (Rluc). (E). HEK293 cellswere co-transfectedwith 50 ng of empty (mock) or the indicatedMAVS plasmids,
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action between the MAVS mutants was observed in the BRET satura-
tion assay (green triangles, Fig. 3D), and the saturation proﬁle was
unaffected even when NS3/4A was coexpressed (yellow triangles,
Fig. 3D). In contrast, the BRET saturation proﬁle of the wild-type
counterparts was impaired when they were coexpressed with NS3/4A
(red squares, Fig. 3D), due to the cleavage of MAVS (Fig. 1B). Theseresults are consistent with the fact that the cytosolic-distributed
MAVS mutants (amino acids 1–514) abolished homotypic MAVS inter-
actions (opened circles, Fig. 1D). Moreover, our BRET results are also
supported by the ﬁndings of Lamarre and colleagues, who reported
that an HCV protease inhibitor did not disrupt the MAVS interaction
even when coexpressed with NS3/4A, as monitored by their BRET sys-
tem [22].
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Mitochondrial proteins NLRX1 and Mfn2 are reported to play in-
hibitory roles in the RLRs pathway [16,23–25]. However, whether or
not these inhibitors affect MAVS–MAVS interaction is unclear. We
next investigated how NLRX1 and Mfn2 affect MAVS interaction bymonitoring their effects via BRET, which is sensitive to miniscule
changes in protein conformation.
3.4.1. NOD-like receptor family member X1 (NLRX1)
HEK293 cells were co-transfected with the BRET pairs of MAVS
constructs (Venus- and Rluc-) with the NLRX1 plasmid. We observed
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cells were co-transfected with 5 ng of Rluc-tagged MAVS constructs and increasing amounts (0−200 ng) of Venus-tagged MAVS plasmids along with (red and yellow) or without
(blue and green) HA-tagged NS3/4A plasmid (100 ng). Graphs of BRET saturation assays are plotted as a function of the ratio of the ﬂuorescence of the acceptor (Venus) to the
luminescence of the donor (Rluc). Squares, WT construct; triangles, mutant construct.
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MAVS interactions, even in the presence of exogenous NLRX1 (red
circles, Fig. 4A). To examine the submitochondrial localization of the
expressed NLRX1, isolated mitochondria from the cells were treated
with trypsin in the absence or presence of digitonin. We conﬁrmed
that NLRX1 was resistant to tryptic digestion even in the presence of
digitonin, which similarly behaved as a matrix protein (mtHsp70),
whereas the treatment drastically degraded outer membrane (MAVS,
Mfn1, Mfn2, and Tom20) or intermembrane (Cyt c) space proteins
(Fig. 4B). The results of this assay implied that the vast majority of
NLRX1 was translocated to the mitochondrial matrix, as previously
reported [26], further supporting the observation that the NLRX1 ex-
pression did not affect the structural rearrangement of cytosol-faced
MAVS oligomerization (Fig. 4A).
An interesting structural feature of NLRX1 is that it possesses an
N-terminal addressing sequence that is essential for mitochondrial
targeting [26,27]. When we masked the addressing sequence by
attaching an N-terminal hemagglutinin tag (N-term) or deleting its
signal sequence (ﬁrst 39 amino acids) (mature), we found that the
expression of these variants affected the MAVS–MAVS interaction
(interfered with the MAVS association), which was detected via
BRET saturation assay (blue squares and red triangles, Fig. 4C). How-
ever, the BRET signal of the C-terminal HA version of NLRX1 protein
behaved similarly to that of the intact protein (yellow circles,
Fig. 4C and Supplementary Fig. S7), suggesting that the subcellular lo-
calization of the mitochondrial protein ultimately affected the MAVS–
MAVS interaction (Fig. 4C, D). We conﬁrmed that the observed BRET
data on MAVS–MAVS interaction with the truncated NLRX1 was not
attributable to a nonspeciﬁc jamming of the TOM/TIMmachinery, be-
cause other controls that normally target the mitochondrial matrix
(Tfam) or inner membrane (O.S. and T.K., unpublished data) and its
mutants lacking part of the mitochondrial addressing sequences
exhibited ﬁne hyperbolic saturated curves (Supplementary Fig. S8).
3.4.2. Mitofusin 2 (Mfn2)
On the other hand, integral mitochondrial outer membrane protein
Mfn2 differentially targeted the MAVS–MAVS interaction and de-
creased the BRET signal (red squares, Fig. 5A), conﬁrming that abundant
Mfn2 rearranged MAVS oligomerization in a dose-dependent manner
(Supplementary Fig. S9). Having identiﬁed that Mfn2 affected MAVS
homotypic interactions, we performed structure-function analyses to
deﬁne theMfn2 region responsible for this modulation. Three dissected
fragments of Mfn2 (GTPase, 4,3 hydrophobic heptad repeat region 1
[HR1], and HR2 regions; see Supplementary Fig. S10) were tested for
their ability to interferewithMAVSoligomerization. Of these fragments,
the middle region of Mfn2 (Mfn2/HR1) was capable of creating a BRET
saturation curve similar to that of the full-length molecule (yellow tri-
angles, Fig. 5B). As expected, the functional role of the HR1 region cor-
related with our BRET data, and we conﬁrmed that abundant Mfn2/
HR1 suppressed IRF-3 activation (right panel, Fig. 5B), as we previously
observed via reporter assay [16]. In addition, overexpression of the
Mfn2/HR1 fragment in HEK293 cells potently and dose-dependently in-
terfered with the complementation of the Venus ﬂuorescence signal by
prohibiting MAVS–MAVS interactions (Fig. 5C), thereby decreasing the
BiFC BRET signal (Fig. 5D). Taken together, these results indicate that
Mfn2 modulates MAVS inactivation on the mitochondrial outer mem-
brane through its HR1 region.
4. Discussion
During the activation of MAVS, a scaffold protein on the outer mito-
chondrial membrane, various downstream effectors are recruited to
form a signaling supramolecular assembly that ultimately leads to the
upregulation of NF-κB and IRF-3 [1,2,4,13]. Despite the many efforts to
identify adaptor molecules that interact with MAVS, it remains poorly
understood how the scaffold protein undergoes itsmulti-step structuraltransition between inactive to active conformations. In the present
study, we used a BRET-based assay to evaluate the MAVS-regulatory
mechanism in live cells, which is in a transient state on the mitochon-
drial outer membrane.
4.1. Activation of MAVS molecules
On the basis of ﬂuorescence assays, two other groups previously
reported that MAVS dimerization is essential for downstream signal
transduction of the RLRs pathway [22,28]. In particular, Wang and
colleague reported that the formation of MAVS homodimers leads
MAVS activation and to bind to a downstream molecule, TRAF3 [28].
Our results agree with their assumption that MAVS homotypic oligo-
merization is involved in MAVS signaling, although we strongly be-
lieve that the activated conformation of MAVS is much more highly
oligomerized than they detected, containing at least more than
three molecules in the complex unit (Figs. 2 and 6A). Consistent
with our observation, a recent crystal structure analysis revealed
that the trimeric form of TRAF3 recognizes equal stoichiometric com-
position of MAVS molecules [29], implying a post-MAVS activation
state. Interestingly, Chen's group provided evidence in an in vitro
study that viral infection induces the formation of prion-like MAVS
aggregates [21], which would be predicted to be much a larger mass
than our observed oligomers. However, on the basis of our results to-
gether with these assumptions, it is likely that MAVS homotypic olig-
omerization, namely the protein concentration on the mitochondrial
membrane foci, is an essential step in the activation of MAVS signal-
ing. These oligomer formations of the scaffold protein are presumably
essential for downstream signaling in another system, because the
stimulator of interferon genes (STING), an ER-integrated membrane
protein involved in anti-cytosolic DNA innate immunity [30], is
reported to be formed in a homo-oligomeric state in response to stim-
ulation [31].
We propose that the MAVS concentration step (post-RLRs binding
to MAVS) is not only triggered by local foci on the mitochondrial sur-
face, but also by some dynamic rearrangement of membrane compo-
sition (such as inner membrane and/or intermembrane space), which
affects molecular collision via an integrated transmembrane domain
(red arrows, Fig. 6A). In fact, the present study shows dynamic expan-
sion of the intermembrane space in virus-infected cells (Fig. 2C and
Supplementary Fig. S6), and we and others reported that disrupting
the mitochondrial membrane potential, an essential physiologic func-
tion of mitochondria, perturbs MAVS-mediated antiviral signaling
[17,32]. At present, we cannot exclude the possibility that some cyto-
solic factors chaperone MAVS–MAVS associations post-RLRs translo-
cation to MAVS, but there is no doubt that MAVS functions are
interconnected with membrane potency [17].
4.2. Negative regulation of MAVS
Our results indicate that NS3/4A, NLRX1, andMfn2, which are inhib-
itors of the RLRs pathway, differentially affect MAVS (Fig. 6B). First,
NS3/4A is categorized as a target cleavage group, and once this
protein is expressed in the cytosol of the host cell, it proteolytically
inhibits MAVS function. Mislocalization of MAVS from the mitochon-
drial membrane leads to improper unfolding of the protein, resulting
in diminished oligomerization (top model, Fig. 6B), and the idea is
also supported by the ﬁnding that deleting the TM domain in mutant
MAVS abolishes its self-association (Fig. 1D). Although our BRET system
failed to distinguish whether this protease targeted pre- or post-MAVS
activation, we were able to monitor the severe disruption of the BRET
signal (see Fig. 3D). Another type of MAVS inhibitor, 3ABC, a cysteine
protease from hepatitis A [33], is also in this category.
NLRX1 localizes predominantly to the mitochondrial matrix
[26,27] and is also reported to be present on the outer membrane
[23], but how it inhibits MAVS-signaling is unclear. Consistent with
AC
D
0 50 100 150 200
Venus DNA (ng)
BR
ET
 
si
gn
al
0
0.2
0.4
0.6
+ Mock
+ NLRX1 (intact)
0
0.2
0.6
BR
ET
 
si
gn
al
0 50 100 150 200
Venus DNA (ng)
0.4
+ Mock
+ mature
+ NACHT
+ C-term
+ N-term
B
IB: α-MAVS
IB: α-Mfn1
75kD
IB: α-NLRX1
75kD
100kD
Mitochondria
Trypsin
Digitonin
- +
+ +
- +
+
+
-
IB: α-Mfn2
IB: α-CoxIV
75kD
15kD
IB: α-mtHsp70 75kD
IB: α-OPA-1
75kD
100kD
15kDIB: α-Tom20
15kD
IB: α-Cyt c
C-termmature
NACHT N-term
Fig. 4. BRET saturation assays in the presence of NLRX1 and its variants. (A). HEK293 cells were co-transfected with 5 ng of the Rluc-MAVS expression plasmid and increasing
amounts (0−200 ng) of the Venus-MAVS plasmid along with either 100 ng of NLRX1 or control (mock) plasmids, and were analyzed 20 h later using a BRET saturation assay.
In this assay, we used a matrix-targeted DHFR (mtDHFR) plasmid as the mock. (B). HEK293 cells were transfected with the NLRX1 expression plasmid, and the puriﬁed mitochon-
drial fraction from the cells was treated with trypsin (100 μg/mL) in the absence (−) or presence (+) of 0.05% digitonin. The reactants were determined by Western blot analysis
with several mitochondrial protein antibodies as indicated. Mitochondrial outer membrane proteins: MAVS, Mfn1, Mfn2, and Tom20. Intermembrane space protein: cytochrome c.
Inner membrane proteins: OPA-1 and Cox IV. Matrix protein: mtHsp70. (C). Similar to (A), except that 100 ng of NLRX1 variant plasmids was used. All data shown represent mean
values±s.d. (n=3). ***Pb0.01. (D). Subcellular localization of NLRX1 variants was monitored by confocal microscopy. The indicated constructs (HA-tagged) were retrovirally
expressed in NLRX1-deﬁcient MEFs and immunoﬂuorescence against the HA epitope (green), and mitochondria were labeled with a mitochondrial-targeted red ﬂuorescent protein.
Each image is a single confocal section from selected cells (scale bar, 10 μm), and enlarged views of the boxed area are shown in the inset column (scale bar, 5 μm).
1024 O. Sasaki et al. / Biochimica et Biophysica Acta 1833 (2013) 1017–1027
AB
C
2000
4000
6000
8000
R
el
at
iv
e 
flu
or
es
ce
nc
e
Venus pair (total ng)
0 50 100 150 200
D
0 50 100 150 200
Venus DNA (ng)
BR
ET
 
si
gn
al
0
0.2
0.4
0.6
0.8
+ Mock
+ Mfn1
+ Mfn2
0
0.4
0.6
BR
ET
 
si
gn
al
0 50 100 150 200
Venus DNA (ng)
0.2
+ Mock
+ Mfn2/HR2
+ Mfn2/GTPase
+ Mfn2/HR1
+ Mfn2
0
0.2
0.5
Bi
FC
 B
RE
T 
si
gn
al
0 50 100 150 200
Venus pair (total ng)
0.1
0.3
0.4
+ Mock
+ Mfn2/HR1
+ Mfn2
+ Mfn1
+ Mock
+ Mfn2/HR1
+ Mfn2
+ Mfn1
IB: α-pIRF-3
100kD
50kD
IB: α-MAVS
IB: α-Myc
+ Omp25
25kD
+ Mfn2
+ Mfn2/GTPase
+ Mfn2/HR2
+ Mfn2/HR1
75kD
Fig. 5.MAVS oligomerization is blocked by Mfn2 and it variants. (A). HEK293 cells were co-transfected with 5 ng of the Rluc-MAVS expression plasmid with increasing amounts
(0−200 ng) of the Venus-MAVS plasmid along with 100 ng of each Myc-tagged Mfn1, Mfn2, or control (mock) plasmids, and analyzed 20 h later using a BRET saturation assay.
(B). Similar to (A), except that 100 ng of Mfn2 variant plasmids was used. Right panels showWestern blots of post-nuclear lysates from the BRET saturation point of each curve by im-
munoblotting with the indicated antibodies. (C). HEK293 cells were co-transfected with an equal mass of Venus(N)-MAVS and Venus(C)-MAVS expression plasmids together with the
indicated expression plasmids, and the ﬂuorescence signals were quantiﬁed using a luminometer. (D). BiFC BRET experiment using (C), except that the cells were co-transfected with
5 ng of the Rluc-MAVS construct. In these BRET assays, we used an Omp-25 expression plasmid as the control (mock) for the integral outer mitochondrial membrane protein. All data
shown represent mean values±s.d. (n=3). ***Pb0.01.
1025O. Sasaki et al. / Biochimica et Biophysica Acta 1833 (2013) 1017–1027the results of Arnoult and colleagues [26], we conﬁrmed that NLRX1
existed predominantly in the matrix, and our BRET results revealed
that overexpression of NLRX1 did not interfere with the MAVS
conformation (Fig. 4A, C). This is likely due to the fact that NLRX1
does not produce a steric constraint when it localizes at the mito-
chondrial matrix side. Therefore, the most likely explanation for its
mechanism is that NLRX1 bypasses other factors existing in the mito-
chondria, and together they engage in the negative regulation of
MAVS (middle model, Fig. 6B). Recently, Ting and colleagues reported
that the mitochondrial Tu translation elongation factor (TUFM) links
the NLRX1 and RLRs pathways [25], and this might be an excellentcandidate. On the other hand, the expression of either the mature
form or the masking of its mitochondrial targeting sequence using
an epitope tag of NLRX1 proteins did not support this idea. Although
NLRX1 would be translocated predominantly to the mitochondrial
matrix, we cannot exclude the possibility that a small portion of
cytosol-retained NLRX1 acts as our observed phenotype, such as a
mature-form protein in the physiologic condition, and inhibits
MAVS signaling (Fig. 4C, D). This possibility also suggests how gC1qR
(also known as p32 [34]) is involved in the down regulation of the
RLRs pathway [35] (it should be noted that its actual localization is
controversial).
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1026 O. Sasaki et al. / Biochimica et Biophysica Acta 1833 (2013) 1017–1027Finally, the mitochondrial outer membrane protein Mfn2 interacts
with MAVS through its HR1 region, and we propose that it stably se-
questers MAVS on the outer mitochondrial membrane by diluting the
highly homogeneous MAVS concentration to a more heterogeneous
population, resulting in a disruption of apparent MAVS–MAVS inter-
actions (bottom model, Fig. 6B). To strengthen our model, we moni-
tored different migrations of MAVS-containing fractions by size
exclusion chromatography when the endogenous Mfn2 level was
knocked down [16]. In the present study, we observed that Mfn2
dose-dependently deducted the BRET intensity of MAVS oligomeriza-
tion (Supplementary Fig. S9). Thus, we believe that Mfn2 would pre-
vent a homogeneous MAVS concentration state by steric hindrance.
In conclusion, the MAVS conformational changes upon its regula-
tion on the mitochondrial membrane are transient during its antiviral
signal transduction, making the direct determination of its structural
elements difﬁcult. In the present study, BRET analysis provided im-
portant insight into the structural features of MAVS and may lead to
an advanced approach to signal transduction studies.
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